Treating human autoimmune disease by depleting B cells

This publication has 45 references indexed in Scilit:

• Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab)
  Annals of the Rheumatic Diseases, 2002
• Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
  Blood, 2002
• Refractory autoimmune thrombocytopenic purpura treatment with Rituximab
  American Journal of Hematology, 2001
• Hapten-Induced Primary and Memory Humoral Responses Are Inhibited by the Infusion of Anti-CD20 Monoclonal Antibody (IDEC-C2B8, Rituximab)
  Clinical Immunology, 2001
• B Lymphocytes Regulate Dendritic Cell (Dc) Function in Vivo
  The Journal of Experimental Medicine, 2000
• Do B cells drive the diversification of immune responses?
  Immunology Today, 1993
• Induction of autoreactive B cells allows priming of autoreactive T cells.
  The Journal of Experimental Medicine, 1991
• Immunoglobulin deficient rats as donors and recipients of effector cells of allergic encephalomyelitis
  Journal of Neuroimmunology, 1986
• Defective induction of antigen‐reactive proliferating T cells in B cell‐deprived mice II. Anti‐μ treatment affects the initiation and recruitment of T cells
  European Journal of Immunology, 1983
• Intact B-cell activity is essential for complete expression of experimental allergic encephalomyelitis in Lewis rats
  Cellular Immunology, 1982